Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

BCL6 Antibody #4242

Applications Reactivity MW (kDa) Source
W H M (R) 87 to 98 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

The BCL6 Antibody detects endogenous levels of BCL6.

Source / Purification

Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to residues near the carboxy-terminal sequence of human BCL6. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of Ramos and A20 cell extracts using BCL6 Antibody.

Background

Chromosomal translocations result in misregulation of the proto-oncogene BCL6 in patients with B cell-derived non-Hodgkins lymphoma (1). The BCL6 gene is selectively expressed in mature B cells and encodes a nuclear phosphoprotein that belongs to the BTB/POZ zinc finger family of transcription factors (2-3). The BCL6 protein can bind to target DNA sequences of Stat6 and, analogous Stat6, modulate the expression of interleukin-4 induced genes (4). Furthermore, BCL6 restrains p53-dependent senescence, making BCL6 active tumors functionally p53 negative (5). The mitogen-activated protein kinases, ERK-1 and ERK-2, but not JNK, phosphorylate BCL6 at multiple sites, and phosphorylation of Ser333 and Ser343 results in degradation of BCL6 by the ubiquitin/proteasome pathway in B cells (6-7). In addition, BCL6 is acetylated and inhibited in its transcriptional repressor function by the transcriptional co-activator p300 (8).

  1. Ye, B. H. et al. (1993) Science 262, 747-750.
  2. Onizuka, T. et al. (1995) Blood 86, 28-37.
  3. Zollman, S. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 10717-10721.
  4. Harris, M. B. et al. (1999) Mol. Cell. Biol. 19, 7264-7275.
  5. Shvarts, A. et al. (2002) Genes Dev. 16, 681-686.
  6. Moriyama, M. et al. (1997) Oncogene 14, 2465-2474.
  7. Niu, H. et al. (1998) Genes Dev. 12, 1953-1961.
  8. Bereshchenko, O. R. et al. (2002) Nat. Genet. 32, 606-613.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes